Catalyst Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 635.87, 718.19, 792.38, 877.38, 930.15 ], "ebit_estimate": [ 293.7, 375.5, 458.73, 343.24, 407.95 ], "ebitda_estimate": [ 337.26, 406.5, 427.99, null, null ], "net_income_estimate": [ 241.6, 290.31, 225.66, 271.54, 321.48 ], "per_share_eps_estimate": [ 1.98, 2.48, 1.89, 2.27, 2.67 ], "eps_nri_estimate": [ 1.95, 2.48, 1.89, 2.27, 2.67 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 9.53, null, null, null, null ], "pretax_income_estimate": [ 329.42, 417.19, 300.88, 455.31, 459.99 ], "operating_cash_flow_per_share_estimate": [ 1.97, 2.67, null, null, null ], "roa_estimate": [ 15.6, null, null, null, null ], "roe_estimate": [ 37.77, 23.61, 19.93, null, null ], "gross_margin_estimate": [ 86.8, 86.75, 90.4, 88.1, 90 ], "operating_cash_flow_estimate": [ 250, 338.83, null, null, null ], "pettm_estimate": [ 15.9, 12.72, 16.65, 13.87, 11.79 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "10.65", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 10.65, "future_ebit_estimate_growth": 21.83, "future_ebitda_estimate_growth": 13.84, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 1.8, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 155.32, 161.6, 169.74, 171.07, 174.41, 176.89, 179.7 ], "ebit_estimate": [ 76.54, 79.96, 83.78, 81.58, 84.84, 87.07, 84.17 ], "ebitda_estimate": [ 81.54, 84.2, 89.31, null, null, null, null ], "net_income_estimate": [ 56.34, 61.22, 65.35, 71.47, 70.22, 73.4, 75.22 ], "per_share_eps_estimate": [ 0.49, 0.5, 0.52, 0.56, 0.55, 0.57, 0.59 ], "eps_nri_estimate": [ 0.49, 0.5, 0.52, 0.56, 0.55, 0.57, 0.59 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ 8.5, 8.98, 9.5, null, null, null, null ], "pretax_income_estimate": [ 70.42, 76.52, 81.69, 89.34, 87.77, 91.75, 94.02 ], "operating_cash_flow_per_share_estimate": [ 0.6, 0.63, -0.02, null, null, null, null ], "roa_estimate": [ 4.1, 4.2, 4.5, null, null, null, null ], "roe_estimate": [ 35.85, 37.44, 37.94, null, null, null, null ], "gross_margin_estimate": [ 86.8, 86.85, 86.85, 82.9, 82.9, 82.9, 82.9 ], "operating_cash_flow_estimate": [ 76.14, 79.95, -2.54, null, null, null, null ], "pettm_estimate": [ 15.28, 14.81, 14.34, 13.87, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "10.65", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 10.65, "future_ebit_estimate_growth": 21.83, "future_ebitda_estimate_growth": 13.84, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": 1.8, "future_operating_cash_flow_per_share_estimate_growth": null }